Treating MS after surviving PML: Discrete strategies for rescue, remission, and recovery patient 1: From the National Multiple Sclerosis Society Case Conference Proceedings

Neurol Neuroimmunol Neuroinflamm. 2020 Dec 15;8(1):e929. doi: 10.1212/NXI.0000000000000929. Print 2021 Jan.
No abstract available

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Crotonates / therapeutic use*
  • Female
  • Humans
  • Hydroxybutyrates / therapeutic use*
  • Immunologic Factors / adverse effects*
  • Immunosuppressive Agents / therapeutic use*
  • Leukoencephalopathy, Progressive Multifocal / chemically induced*
  • Leukoencephalopathy, Progressive Multifocal / diagnosis
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / adverse effects*
  • Nitriles / therapeutic use*
  • Toluidines / therapeutic use*

Substances

  • Crotonates
  • Hydroxybutyrates
  • Immunologic Factors
  • Immunosuppressive Agents
  • Natalizumab
  • Nitriles
  • Toluidines
  • teriflunomide